TW201934132A - 禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途 - Google Patents
禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途 Download PDFInfo
- Publication number
- TW201934132A TW201934132A TW107105385A TW107105385A TW201934132A TW 201934132 A TW201934132 A TW 201934132A TW 107105385 A TW107105385 A TW 107105385A TW 107105385 A TW107105385 A TW 107105385A TW 201934132 A TW201934132 A TW 201934132A
- Authority
- TW
- Taiwan
- Prior art keywords
- poultry
- protein extract
- crude protein
- crude
- phenylalanine
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 78
- 235000019750 Crude protein Nutrition 0.000 title claims abstract description 55
- 244000144977 poultry Species 0.000 title claims abstract description 48
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 235000013594 poultry meat Nutrition 0.000 claims abstract description 60
- 239000004310 lactic acid Substances 0.000 claims abstract description 30
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 30
- 210000004369 blood Anatomy 0.000 claims abstract description 29
- 239000008280 blood Substances 0.000 claims abstract description 29
- 210000003205 muscle Anatomy 0.000 claims abstract description 27
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 22
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims abstract description 21
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000004472 Lysine Substances 0.000 claims abstract description 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 15
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 14
- 230000004060 metabolic process Effects 0.000 claims abstract description 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004473 Threonine Substances 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 6
- 210000004185 liver Anatomy 0.000 claims description 32
- 108010066207 Poultry Proteins Proteins 0.000 claims description 17
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 10
- 241000272525 Anas platyrhynchos Species 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 6
- 241000271566 Aves Species 0.000 claims description 5
- 230000037080 exercise endurance Effects 0.000 claims description 5
- 229940113082 thymine Drugs 0.000 claims description 5
- 241000272814 Anser sp. Species 0.000 claims description 3
- 241000272201 Columbiformes Species 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 abstract description 5
- 229940096919 glycogen Drugs 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 43
- 241000700159 Rattus Species 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- 230000009182 swimming Effects 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 102000006587 Glutathione peroxidase Human genes 0.000 description 13
- 108700016172 Glutathione peroxidases Proteins 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 102000016938 Catalase Human genes 0.000 description 11
- 108010053835 Catalase Proteins 0.000 description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 description 11
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 238000012453 sprague-dawley rat model Methods 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 9
- 229960003646 lysine Drugs 0.000 description 9
- 238000001543 one-way ANOVA Methods 0.000 description 9
- 230000004792 oxidative damage Effects 0.000 description 9
- 229960005190 phenylalanine Drugs 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 8
- 229960002885 histidine Drugs 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 230000003859 lipid peroxidation Effects 0.000 description 6
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 5
- 238000012742 biochemical analysis Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960002898 threonine Drugs 0.000 description 5
- 108010056594 Avian Proteins Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 208000029549 Muscle injury Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- KUNFMZSTKSLIEY-GRHHLOCNSA-N (2s)-2-azanyl-3-phenyl-propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 KUNFMZSTKSLIEY-GRHHLOCNSA-N 0.000 description 1
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical group CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000272834 Cairina moschata Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000209501 Spirodela Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013364 duck meat Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 229940091868 melamine Drugs 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/02—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from meat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本發明提供一種禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,在經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine);其中該抗疲勞包含提高肌肉肝醣濃度、有助於增加運動耐力、有助於提升血液中尿素氮代謝以及有助於抑制乳酸生成。
Description
本發明提供一種禽類粗蛋白萃取物,特別係一種禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途。
疲勞係指身體無法維持在一定水平上運作,各器官無法維持固定的工作能力;即身體因過度活性造成作業肌肉無法維持力量,而導致活動能力下降。
已知疲勞的成因為能量耗竭、代謝產物堆積、自由基損傷之因素。血液中葡萄糖在長時間的運動中進行代謝提供肌肉組織能量,當血糖含量不足以提供充足能量,肝醣便會被分解形成葡萄糖釋放於血液中。研究指出肌肉中肝醣含量可做為長時間肌肉運動的相關指標,而在大量消耗能量時,會促使體內進行無氧醣代謝以在短時間內增加大量ATP,同時也會產生大量乳酸堆積,造成氫離子濃度上升而是pH值下降,導致鈣離子的釋放並降低肌纖維的收縮能力,加快疲勞的發生。有研究指出,肌肉與血液中的乳酸值需5~10分鐘才會達到平衡,而乳酸可藉由轉變為葡萄糖或肝醣等方式去除。因此,加速乳酸的代謝為恢復疲勞之重要指標。
血尿素氮是人體中蛋白質及胺基酸代謝的最終產物,而蛋白質的分解速度與代謝速度則會影響血尿素氮的濃度。運動造成蛋白質與胺基酸激烈分解、腎臟的功能下降、脫水使得血漿量減少而導致腎臟的血流縮減以及蛋白質與胺基酸大量的分解,都會造成血尿素氮的濃度上升。
自由基為原子、分子及離子等元素,其外圍軌道上含有單獨為成對電子之結構,容易結合周遭其他細胞分子之電子而引發一連串的反應造成氧化壓力的產生。在長期或進行激烈運動情形下,自由基會大量的生成,而造成大量的氧化壓力。若抗氧化防禦系統不足以抗衡時,身體細胞組織將產生損傷,導致生理功能發生障礙。
當疲勞產生後會發生反應遲緩與無法進行精密操作等問題,將會增加機器操作上的失誤以及危險的發生。因此,如何從日常生活中補充何種物質或成分預疲勞之發生,一直是食品、營養保健與醫學界之重大課題。
有鑑於此,本發明提供一種禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由85~105℃之高溫高壓萃取9~11小時,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
本發明另提供一種禽類粗蛋白萃取物用於製備提高肌肉肝醣濃度之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
本發明另提供一種禽類粗蛋白萃取物用於製備增加運動耐力之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
本發明另提供一種禽類粗蛋白萃取物用於製備提升血液中尿素氮代謝之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
本發明另提供一種禽類粗蛋白萃取物用於製備抑制乳酸生成之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
在本發明之一實施例中,其中該禽類粗蛋白萃取物進一步包含酪胺酸及甲硫胺酸。
在本發明之一實施例中,其中該禽類粗蛋白萃取物之有效劑量為每日攝取至少20 mL。
在本發明之一實施例中,其中該禽類肉品來源為雞、鴨、鵝或鴿子。
本發明之禽類粗蛋白萃取物不會影響動物體重、攝食量、肝臟重量及腎臟重量,對生理代謝無不良之影響。經由肝臟損傷指標(AST、ALT)以及肌肉損傷(CPK、肌酸酐)之數值顯示餵食本發明之禽類粗蛋白萃取物對大鼠之安全性無不良的影響。肝臟及肌肉氧化傷害指標顯示餵食本發明之禽類粗蛋白萃取物後可提高抗氧化酵素的活性,形成保護作用。經過游泳力竭試驗結果得知,餵食本發明之禽類粗蛋白萃取物之游泳時間明顯上升;代謝壓力生化指標評量結果顯示乳酸產生方面,餵食本發明之禽類粗蛋白萃取物之乳酸產生較低;在肝臟及肌肉肝醣濃度方面,餵食本發明之禽類粗蛋白萃取物之肌肉肝醣濃度呈現顯著增加。因此,本發明之禽類粗蛋白萃取物具有提高肌肉肝醣濃度、有助於增加運動耐力、有助於提升血液中尿素氮代謝以及有助於抑制乳酸生成之功效。
以下將配合圖式進一步說明本發明的實施方式,下述所列舉的實施例係用以闡明本發明,並非用以限定本發明之範圍,任何熟習此技藝者,在不脫離本發明之精神和範圍內,當可做些許更動與潤飾,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。
當疲勞產生後會發生反應遲緩、無法進行精密操作,故會增加操作上的失誤以及危險發生。當人體進行缺氧或激烈運動時,會藉由肝醣轉換成葡萄糖而提升體內血糖濃度,經由糖解作用(Glycolysis)以提供肌肉組織充分的能量、減少無氧運動後人體內乳酸的產生、及時清除乳酸或是增加體內抗氧化物質皆可達到抗疲勞的效果。
本發明提供一種禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途,本發明為評估禽類粗蛋白萃取物對抗疲勞功能之影響,參照衛生福利部公告之「健康食品之抗疲勞功能評估方法」規範,以9周齡Sprague-Dawley(SD)品系雄性大鼠進行試驗,每組8隻,分別為控制組、低劑量組、中劑量組及高劑量組。經8周餵食本發明之禽類粗蛋白萃取物後,進行體能挑戰與消除疲勞指標之評估。定義
本文所述之禽類粗蛋白萃取物包含雞、鴨、鵝及鴿子等禽類之粗蛋白萃取物。
本文所述之「抗疲勞」是指提高肌肉肝醣濃度、有助於增加運動耐力、有助於提升血液中尿素氮代謝以及有助於抑制乳酸生成。
如於本文中所使用數值為近似值,所有實驗數據皆表示在20%的範圍內,較佳為在10%的範圍內,最佳為在5%的範圍內。統計分析
依一般生物統計方法分析,SPSS統計軟體統整後以平均值(mean) ± 標準偏差 (standard deviation,S.D.) 表示。試驗數據利用統計軟體中單因子變異數分析(One-way ANOVA)之鄧肯式多變域測試(Duncan’s Multiple Range Test) 比較試驗物質介入後疲勞挑戰的恢復評量,以英文字母表示統計之結果,相同字母表示組間不具統計上差異(p
>0.05),不相同字母表示組間具統計上差異(p
<0.05)。當試驗物質介入後,在適當的疲勞性挑戰後,恢復評量指標至少有2種類型指標達到統計上的顯著改善(p
<0.05),即可判斷該試驗物質應具有抗疲勞之功能。實施例 1 本發明之禽類粗蛋白萃取物的製備方法
本發明選用15週齡的白色番鴨畜試1號,經屠宰後置於溫度-2℃至7℃的環境下驗收與原物料處理,挑選肉色正常且表面無滲出液、無異味,肉質富彈性的鴨肉裝入壓力鍋後,以設定溫度95℃,減壓濃縮滴取10小時,再經油水分離、85℃熱充填,最後於121℃滅菌15分鐘後獲得本發明之禽類粗蛋白萃取物。實施例 2 本發明之禽類粗蛋白萃取物的成分分析
本發明進一步將實施例1製備的鴨禽類粗蛋白萃取物及以相同方法製備的雞禽類粗蛋白萃取物進行成分分析,結果如表一、表二所示,其中含有胺基酸及蛋白質,以酥胺酸、組胺酸、纈胺酸、苯丙胺酸、異白胺酸、白胺酸以及離胺酸等胺基酸的含量較高,尤其白胺酸為人體所必需之胺基酸,因為該些胺基酸無法由肝臟中合成,必須藉由額外的攝取才能獲得;其可降低疲憊感,對有在進行體能鍛鍊者而言,白胺酸為α-酮異己酸(α-ketoisocaproate,KIC)以及β-羥基-β-甲基丁酸鹽複合物(beta-hydroxy beta-methylbutyrate, HMB)的前驅物,可以增進運動能力,加速肌肉疲勞的恢復速度。再者,在營養成分分析中進一步證實本發明之禽類粗蛋白萃取物不含反式脂肪且飽和脂肪脂含量極少,有益人體健康。 表一、 鴨禽類粗 蛋白萃取物與雞禽類粗蛋白萃取物之胺基酸分析 (mg/100g) 表二、鴨禽類組蛋白萃取物與雞禽類組蛋白萃取物之營養成分分析 實施例 3 本發明之禽類粗蛋白萃取物的抗疲勞評估
本發明為評估禽類粗蛋白萃取物對抗疲勞功能之影響,參照衛生福利部公告之「健康食品之抗疲勞功能評估方法」規範,以9周齡SD品系雄性大鼠(購自樂斯科生物科技股份有限公司)進行試驗,每組8隻,分別為控制組、低劑量組、中劑量組及高劑量組,其所投予本發明之禽類粗蛋白萃取物之低、中、高劑量分別0.58、1.17、2.92 g/kg B.W.(body weight),控制組給予逆滲透水(大鼠口服給予劑量依據成人每日攝取量計算,如表三所示)。表三、 本發明之禽類粗蛋白萃取物各組餵食劑量
a 劑量換算:大鼠口服給予劑量依據成人每日攝取量,再根據大鼠相對人體之代謝係數(6.2)進行換算,計算出大鼠每日口劑量,以每人每日服用1g為例,大鼠劑量為0.103g/kg (1g/60kg × 6.2=0.103 g/kg)。 b 本發明之禽類粗蛋白萃取物餵食8周。規格為65 mL/瓶,凍乾比例8.7 %,所以凍乾後重量為5.66 g/ 瓶。
經8周餵食本發明之禽類粗蛋白萃取物後,進行體能挑戰與消除疲勞指標之評估。體能挑戰為游泳力竭試驗、並於試驗後進行疲勞評估。生理壓力恢復之評量包含代謝壓力指標:含乳酸上升率(Increase lactate rate)、乳酸下降率(Decrease lactate rate)、血尿素氮(BUN)含量。肌肉損傷指標(Muscle damage index):含肌酸酐(Creatinine)、肌酸激酶(Creatinine phosphokinase,CPK)及肌紅蛋白(Myoglobin)。肝臟損傷指標(Liver damage index):含麩胺酸苯醋酸轉胺基酵素(Aspartate aminotransferase,AST)及麩胺酸丙酮酸轉胺基酵素(Alanine Aminotransferase,ALT)活性。氧化傷害指標(Oxidative damage index):含硫代巴比妥酸反應物質(Thiobarbituric acid reactive substances,TBARS)、過氧化經酶(Catalase)、超氧化物歧化酶(Superoxide dismutase,SOD)及谷胱甘肽過氧化物酶(Glutathione peroxidase,GPx)活性。
開始試驗前,大鼠經過1周入室檢疫及適應,使大鼠習慣、熟悉新的環境。第1天試驗開始,每日管餵本發明之禽類粗蛋白萃取物,持續至第56天;第49天進行游泳訓練,以利之後進游泳試驗;第52天進行負重3%游泳力竭試驗;第53天進行90分鐘游泳試驗後,測定血尿素氮(BUN)值;第55天進行10分鐘油用試驗後,測定游泳前、游泳後與休息20分鐘後血清乳酸值;第56天進行動物犧牲及採血後進行生理生化分析。3.1 體重及攝食量測定
試驗動物於給予開始前、試驗期間每周量測一次動物體重及攝食量;且試驗期間每周進行結算1次,量測方法為體重秤重當日加入定量飼料,一周後結算剩餘飼料量。如表四及表五所示,試驗結果顯示,試驗第1至8周低、中、高劑量平均體重及攝食量與控制組相較下,無顯著差異(p
>0.05)。表四、試驗期間各組大鼠平均體重變化
所有數據均以Mean ± S.D.表示,n = 8。以One-Way ANOVA之fmultiple range test比較各組間之差異,以英文字母表示統計之結果,相同字母表示組間不具統計上差異(p
> 0.05),不相同字 母表示組間具統計上差異 (p
< 0.05)。 表五、試驗期間各組大鼠平均攝食量變化
所有數據均以Mean ± S.D.表示,n = 8。以One-Way ANOVA之Duncan's multiple range test比較各組間之差異,以英文字母表示統計之結果,相同字母表示組間不具統計上差異 (p
> 0.05),不相同字母表示組間具統計上差異 (p
< 0.05)。3.2 肝臟及腎臟之重量測定
試驗結束大鼠犧牲時,秤取各組大鼠主要臟器肝、腎臟之重量,並進行統計分析。試驗期間結果如表六所示,各組大鼠肝、腎臟之重量與控制組相比較,並無顯著差異(p
>0.05)。表六、各組大鼠肝臟與腎臟平均重量
所有數據均以Mean ± S.D.表示,n = 8。以One-Way ANOVA之Duncan's multiple range test比較各組間之差異,以英文字母表示統計之結果,相同字母表示組間不具統計上差異 (p
> 0.05),不相同字母表示組間具統計上差異 (p
< 0.05)。3.3 游泳力竭試驗
實驗前一周,在餵食30分鐘後,先前進行游泳訓練。於試驗前禁食12小時後,將大鼠放入直徑45 cm、水深50 cm、水溫27±1℃的塑膠水桶中進行負重游泳,負重比率為體重之3 %,強迫大鼠進行游泳掙扎,直到體力消耗殆盡下沈為止,計算自落水開始至鼻孔沈入水中10秒即為游泳時間。
各組大鼠游泳力竭時間結果如表七所示,餵食低、中、高劑量之本發明之禽類粗蛋白萃取物後,大鼠游泳時間與控制組相比,可由442.3秒分別提升到598.8秒、571.3秒及585.6秒,可發現動物在餵食本發明之禽類粗蛋白萃取物後游泳時間增長,呈現顯著差異(p
<0.05),但在各劑量間無明顯差異(p
>0.05)。表七、各組大鼠游泳力竭時間
所有數據均以Mean ± S.D.表示,n = 8。以One-Way ANOVA之Duncan's multiple range test比較各組間之差異,以英文字母表示統計之結果,相同字母表示組間不具統計上差異 (p
> 0.05),不相同字母表示組間具統計上差異 (p
< 0.05)。3.4 乳酸生化分析檢測
進行10分鐘游泳試驗後,測定游泳前、游泳後與休息20分鐘後血清乳酸值,取得血清並以血清生化分析儀(7070 Autoanalyzer,日立)乳酸含量。游泳力竭試驗後乳酸含量之變化,由表八結果可發現,低、中及高劑量組之乳酸上升率與控制組相比有明顯減少,呈現顯著差異(p
<0.05);然而,各劑量組之乳酸下降率與控制組相比則無顯著差異(p
>0.05)。此外,乳酸上升率與乳酸下降率於各劑量間無明顯差異(p
>0.05)。3.5 血尿素氮生化分析檢測
進行90分種游泳試驗後,測定血尿素氮含量(BUN)。取得血清並以血清生化分析儀(7070 Autoanalyzer,日立)檢測血漿中血尿素氮含量。血尿素氮含量分析結果如表八所示,可發現餵食本發明之禽類粗蛋白萃取物後,各劑量組之血尿素氮值顯著低於控制組(p
<0.05),但在各劑量間無明顯差異(p
>0.05)。3.6 肝臟與肌肉組織肝臟分析
本次餵食30分鐘後犧牲動物,取肝臟與小腿腓腸肌,並將肝醣分解為葡萄糖,以市售套組蔥酮試劑進行肝醣檢測。肝臟與肌肉肝醣濃度之分析結果如表八所示,肝臟肝醣濃度結果顯示,低、中及高劑量組與控制組相比,則無顯著差異(p
>0.05);肌肉肝醣濃度結果顯示,低、中及高劑量組與控制組相比呈現顯著增加(p
<0.05),但在各劑量間無明顯差異(p
>0.05)。表八、各組大鼠血尿素氮、乳酸上升及乳酸下降率、肝臟及肌肉肝醣分析結果
所有數據均以Mean ± S.D.表示,n = 8。以One-Way ANOVA之Duncan's multiple range test比較各組間之差異,以英文字母表示統計之結果,相同字母表示組間不具統計上差異 (p
> 0.05),不相同字母表示組間具統計上差異 (p
< 0.05)。3.7 肝臟與肌肉組織氧化傷害指標因子分析
本發明經由含硫代巴比妥酸反應物質(Thiobarbituric acid reactive substances,TBARS)、過氧化經酶(Catalase)、超氧化物歧化酶(Superoxide dismutase,SOD)及谷胱甘肽過氧化物酶(Glutathione peroxidase,GPx)活性檢測肝臟與肌肉組織氧化傷害程度。
硫代巴比妥酸(thiobarbituric acid,TBA) 反應物質係參考Tarladgis et al. 之脂質過氧化分析法,以1,1,3,3-tetramethoxy-propane(TMP)為標準品,先以二次蒸餾水將TMP稀釋為1 mM,再以1 N H2
SO4
溶液將其濃度分別稀釋為0、20、40、60、80、100 μM,各取100 μL進行分析,分析方法與樣品相同。取100 μL的組織萃取液加入600 μL的5 % 三氯乙酸(trichloroacetic acid)以及200 μL 60 mmol/L的TBA,於80 ℃反應90分鐘後,冷卻至室溫,在經離心後(12,000×g,15 min,4 ℃),去上清液以供丙二醛(malondialdehyde,MDA)濃度之分析。丙二醛與硫代巴比妥酸溶液在酸性環境下,加熱一段時間後會生成粉紅色物質,並在波長540 nm下測定吸光值,以推算檢體之「脂質過氧化」程度。硫代巴比妥酸是分析脂質過氧化作用所產生的產物,一般以MDA的產量表示,檢測單位以μM/g蛋白質表示之。
過氧化氫酶(Catalase)測定原理為過氧化氫酶能催化H2
O2
分解為H2
O及O2
,而使H2
O2
吸光值隨時間增加而減少,由於反應量與吸收值減少速率呈比例關係,因此可依H2
O2
分解速率來定量過氧化氫酶活性。過氧化氫酶之活性以U/g蛋白質表示。以磷酸鹽緩衝液(Phosphate Buffered Saline,PBS;0.05 M NaH2
PO4
及Na2
HPO4
)稀釋H2
O2
,使其吸光值約1.2~1.3之間進行試驗,配製過氧化氫酶(20、40、60、70、80、90、100 unti/mL/蛋白質),取900 μL H2
O2
稀釋液與100 μL樣品均勻混合後,利用分光光度計檢測3分鐘內波長230 nm吸光值變化量,進行定量分析。
超氧化物歧化酶(Superoxide dismutase,SOD)活性分析依據SOD活性檢驗試劑Ransod(RANDOX Lab. Ltd,英國)。SOD活性定義為抑制2-(4-碘-苯基)-3-(4-硝基-苯基)-5-苯基四唑化氯(2-(4-iodo-phenyl)-3-(4-nitro-phenyl)-5- phenyltetrazolium chloride)還原反應速率50%所需酵素的量為一單位(U),檢測單位以U/mg 蛋白質表示。
谷胱甘肽過氧化物酶(Glutathione peroxidase,GPx)檢測係依據GPx活性檢驗試劑Ransel(RANDOX Lab. Ltd,英國)。GPx活性定義為每分鐘氧化1 mole NADPH所需酵素的量為一單位(U) ,組織的GPx活性以U/mg 蛋白質表示。
各組大鼠肝臟氧化傷害指標如表九所示,低、中及高劑量組之GPx活性顯著均高於控制組(p
<0.05);低劑量組之SOD活性與控制組相較則無顯著差異(p
>0.05),而中及高劑量組與控制組相較下,SOD活性顯著提升(p
<0.05);低、中及高劑量組之過氧化氫酶活性高於控制組(p
<0.05),各劑量間則無顯著差異(p
>0.05);各劑量組之硫代巴比妥酸反應物質(TBARS)含量與控制組相比,顯著降低(p
<0.05),而各劑量組無組間之差異(p
>0.05)。表九、各組大鼠肝臟組織氧化傷害指標分析結果
所有數據均以Mean ± S.D.表示,n = 8。以One-Way ANOVA之Duncan's multiple range test比較各組間之差異,以英文字母表示統計之結果,相同字母表示組間不具統計上差異 (p
> 0.05),不相同字母表示組間具統計上差異 (p
< 0.05)。
各組大鼠肌肉氧化傷害指標如表十所示,低、中及高劑量組之GPx活性均顯著高於控制組(p
<0.05);中、高劑量組之SOD活性均高於控制組(p
<0.05);低、中及高劑量組之過氧化氫酶活性與控制組,則相比顯著增加(p
<0.05);而GPx、SOD及過氧化氫酶活性於各劑量組皆無組間差異(p
>0.05);TBARS之各劑量組與控制組相比,顯著降低(p
<0.05)。表十、各組大鼠肌肉組織氧化傷害指標分析結果
所有數據均以Mean ± S.D.表示,n = 8。以One-Way ANOVA之Duncan's multiple range test比較各組間之差異,以英文字母表示統計之結果,相同字母表示組間不具統計上差異 (p
> 0.05),不相同字母表示組間具統計上差異 (p
< 0.05)。3.8 血清生化分析
事件結束時,使用吸入二氧化碳方式將所有試驗大鼠進行犧牲進行血液採樣。經4 ℃、3,000×g條件下離心15分鐘,取得血清並以血清生化分析儀(7070 Autoanalyzer,日立)及相關試劑檢測血清樣本中之天冬氨酸氨基轉移酶(Aspartate aminotransferase,AST)、丙氨酸氨基轉移酶(Alanine aminotransferase,ALT)、葡萄糖(Glucose)、血尿素氮(BUN)與肌酸酐(Creatinine)。
各組大鼠血清生化檢測結果如表十一所示,各組之肝臟損傷指標(AST、ALT)之數值均無顯著差異(p
>0.05)。3種肌肉損傷指標(CPK、肌酸酐、肌紅蛋白),而低、中及高劑量組之CPK、肌酸酐濃度與控制組相較下,數值均無顯著差異(p
>0.05)。各劑量之肌紅蛋白濃度與控制組相較下,顯著增加(p
>0.05)。在血糖值方面,各組間也並無顯著差異(p
>0.05)。表十一、各組大鼠血清生化分析結果
所有數據均以Mean ± S.D.表示,n = 8。以One-Way ANOVA之Duncan's multiple range test比較各組間之差異,以英文字母表示統計之結果,相同字母表示組間不具統計上差異 (p
> 0.05),不相同字母表示組間具統計上差異 (p
< 0.05)。
綜上所述,各劑量組平均體重、平均攝食量及大鼠肝、腎臟之重量與控制組比較;代表餵食本發明之禽類粗蛋白萃取物對生理代謝無不良反應之影響。餵食低、中、高劑量之本發明之禽類粗蛋白萃取物後,其大鼠游泳時間與控制組相比,可442.3秒分別提升到598.8秒、517.3秒即585.6秒游泳時間增長,表示具提升大鼠基礎體力之效果。血尿素氮分析結果,各劑量組之血尿素氮值顯著低於控制組,表示由低劑量組起,即具有加快蛋白代謝的能力,而降低血尿素氮的含量。游泳力竭試驗後乳酸含量之變化,由結果顯示,經過游泳試驗後乳酸含量會因疲勞而增加,休息後也會因乳酸代謝而逐漸降低。由血漿中乳酸分析結果可知,各劑量組大鼠給予本發明之禽類粗蛋白萃取物,於運動測試後,可抑制乳酸之形成,而減緩乳酸堆積。肌肉肝醣濃度之分析結果,各劑量組與控制組相比,呈現顯著增加。表示可藉由提高肌肉肝醣濃度、增加抗疲勞之效果。血清生化指標分析結果可知,各組間之肝臟損傷指標(AST、ALT)之數值均無顯著差異;肌肉損傷(CPK、肌酸酐)之數值均無顯著差異,顯示餵食本發明之禽類粗蛋白萃取物對大鼠之安全性無不良的影響。各劑量組之肝臟及肌肉CPx、過氧化氫酶活性均顯著高於控制組,顯示餵食本發明之禽類粗蛋白萃取物後,可提高抗氧化酵素的活性,形成保護作用。在氧化傷害指標方面,TBARS為脂質過氧化反應脂標之一。因此,劇烈運動後,脂質過氧化物會顯著增加,由結果顯示,本發明之禽類粗蛋白萃取物可顯著降低肝臟與肌肉TBARS數值,各劑量組間對於改善肝臟與肌肉脂質過氧化現象,則顯著差異。因此,本發明之禽類粗蛋白萃取物具有提高肌肉肝醣濃度、有助於增加運動耐力、有助於提升血液中尿素氮代謝以及有助於抑制乳酸生成之功效。
無。
無。
Claims (8)
- 一種禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由85~105℃之高溫高壓萃取9~11小時,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
- 一種禽類粗蛋白萃取物用於製備提高肌肉肝醣濃度之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
- 一種禽類粗蛋白萃取物用於製備增加運動耐力之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
- 一種禽類粗蛋白萃取物用於製備提升血液中尿素氮代謝之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
- 一種禽類粗蛋白萃取物用於製備抑制乳酸生成之組合物的用途,其中該禽類粗蛋白萃取物係一禽類肉品經由高溫高壓萃取,再經由油水分離去除油脂後而獲得,且該禽類粗蛋白萃取物至少包含支鏈胺基酸(Branched- chain amino acid,BCAA)、組胺酸(Histidine)、酥胺酸(Threonine)、離胺酸(Lysine)以及苯丙胺酸(Phenylalanine)。
- 如申請專利範圍第1項至第5項任一項所述之用途,其中該禽類粗蛋白萃取物進一步包含酪胺酸及甲硫胺酸。
- 如申請專利範圍第1項至第5項任一項所述之用途,其中該禽類粗蛋白萃取物之有效劑量為每日攝取至少20 mL。
- 如申請專利範圍第1項至第5項任一項所述之用途,其中該禽類肉品來源為雞、鴨、鵝或鴿子。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107105385A TW201934132A (zh) | 2018-02-13 | 2018-02-13 | 禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途 |
US16/253,190 US11052058B2 (en) | 2018-02-13 | 2019-01-21 | Use of poultry crude protein extract for preparing anti-fatigue composition |
CN201910102624.7A CN110151969A (zh) | 2018-02-13 | 2019-02-01 | 禽类粗蛋白萃取物用于制备抗疲劳的组合物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107105385A TW201934132A (zh) | 2018-02-13 | 2018-02-13 | 禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201934132A true TW201934132A (zh) | 2019-09-01 |
Family
ID=67541924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107105385A TW201934132A (zh) | 2018-02-13 | 2018-02-13 | 禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11052058B2 (zh) |
CN (1) | CN110151969A (zh) |
TW (1) | TW201934132A (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102388658B1 (ko) * | 2020-05-11 | 2022-04-20 | (주)에이치엔에프 | 닭가슴살을 이용한 반려동물용 식품의 제조방법 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5757524A (en) * | 1981-06-22 | 1982-04-06 | Terumo Corp | Apparatus for monitoring urine amount |
JPS617102A (ja) * | 1984-06-18 | 1986-01-13 | Shigekazu Takeda | カ−ドによるキ−等の自動取出し、収納方法およびシステム |
JP3617102B2 (ja) * | 1995-01-27 | 2005-02-02 | 味の素株式会社 | ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物 |
US20060093649A1 (en) | 2002-10-11 | 2006-05-04 | Ajinomoto Co., Inc. | Food composition for recovery from fatigue |
TWI256882B (en) | 2005-07-15 | 2006-06-21 | Uni President Entpr Corp | A method for producing an immunostimulating chicken essence |
CN103766736B (zh) * | 2014-01-21 | 2015-12-30 | 中国人民解放军第三军医大学 | 抗疲劳能量组合物及其应用 |
CN104587151A (zh) * | 2015-01-08 | 2015-05-06 | 中国药科大学 | 一种缓解疲劳的中药复合物及其制备方法和应用 |
TWI586357B (zh) | 2016-04-25 | 2017-06-11 | Yuan Jin Chuang Enterprise Co Ltd | The use of poultry crude protein extract for the preparation of compositions for enhancing immunity |
CN107397761A (zh) * | 2016-05-20 | 2017-11-28 | 元进庄企业股份有限公司 | 禽类粗蛋白萃取物用于制备增强免疫力的组合物的用途 |
TWM565575U (zh) | 2017-02-13 | 2018-08-21 | 杏輝藥品工業股份有限公司 | 含管花肉蓯蓉萃取物、以及氧化型輔酵素(q10)及/或還原型輔酵素(qh)之物品結構 |
CN107325163B (zh) * | 2017-07-17 | 2020-06-16 | 澳门大学 | 黄芪种子蛋白及其在抗运动疲劳功能食品中的应用 |
-
2018
- 2018-02-13 TW TW107105385A patent/TW201934132A/zh unknown
-
2019
- 2019-01-21 US US16/253,190 patent/US11052058B2/en active Active
- 2019-02-01 CN CN201910102624.7A patent/CN110151969A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110151969A (zh) | 2019-08-23 |
US20190247346A1 (en) | 2019-08-15 |
US11052058B2 (en) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Manal Said et al. | Adverse effects of monosodium glutamate on liver and kidney functions in adult rats and potential protective effect of vitamins C and E | |
Gupta et al. | Anti‐stress and Adaptogenic Activity of l‐Arginine Supplementation | |
Ji et al. | The immunoreaction and antioxidant capacity of juvenile blunt snout bream (Megalobrama amblycephala) involves the PI3K/Akt/Nrf2 and NF-κB signal pathways in response to dietary methionine levels | |
Han et al. | Hepatoprotective effects of the water extract from adzuki bean hulls on acetaminophen-induced damage in rat liver | |
Yang et al. | Dietary phosphorus affects growth, glucolipid metabolism, antioxidant activity and immune status of juvenile blunt snout bream (Megalobrama amblycephala) | |
Song et al. | Purified dietary red and white meat proteins show beneficial effects on growth and metabolism of young rats compared to casein and soy protein | |
Wassie et al. | Enteromorpha polysaccharide and yeast glycoprotein mixture improves growth, antioxidant activity, serum lipid profile and regulates lipid metabolism in broiler chickens | |
TW201934132A (zh) | 禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途 | |
Ates et al. | Effect of dietary Garcinia cambogia extract on serum lipid profile and serum enzymes in rats fed high-lipid diet | |
TAMAKI et al. | Anserine and carnosine contents in muscular tissue of rat and rabbit | |
Cholewa et al. | An overview of betaine supplementation, sports performance, and body composition | |
Lee et al. | Hot water extract of leather carp (Cyprinus carpio nudus) improves exercise performance in mice | |
Liu et al. | Effect of spermine on liver and spleen antioxidant status in weaned rats. | |
Khalaf et al. | Effect of barley (Hordeum vulgare) on the liver of diabetic rats: Histological and biochemical study | |
Milani et al. | Use of Broccoli (Brassica oleracea L. var. Italica) in Comparison to Ascorbic Acid to Decrease Pulmonary Hypertension Syndrome in Broiler Chickens. | |
Oh et al. | Effect of water extract of germinated brown rice on adiposity and obesity indices in mice fed a high fat diet | |
Olivera et al. | Selenium, thiobarbituric acid reactive substances, and thyroid hormone activation in broilers supplemented with selenium as selenized yeast or sodium selenite | |
Petrulea et al. | THYROID HORMONES IN EXCESS INDUCE OXIDATIVE STRESS IN RATS. | |
Khan et al. | Effect of various fractions of Launaea procumbens on antioxidant enzymes in rats liver: Oxidative stress induced by potassium bromate (KBrO3) | |
Warren et al. | Protein quality and safety evaluation of sarcoplasmic protein derived from silver carp (Hypophthalmichthys molitrix) using a rat model | |
Amin et al. | Effect of feeding artichoke and milk thistle on rats treated with CCl4 and glycerol/saline solution | |
Liu et al. | Adjustment of Prescription by ORAC assay to Enhance the Effect of Medicinal Liqueur | |
CN110812383A (zh) | 具有抑制脂肪形成及抗氧化活性的组合物及其用途 | |
El-Batal et al. | Ameliorating effect of yeast Glucan with zinc Bisglycinate in Histological and Biochemical changes in γ-irradiated rats | |
TWI745609B (zh) | 具抗氧化活性之組合物 |